Besides, data from a small cohort of 87 NSCLC participants suggested that the prognosis for immunotherapy in patients with KRAS mutations was significantly worse when co-mutated with CDKN2A/B [137]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.